Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.58 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929351 | 1.00 | P2RX3 (0.58) | P2RX3P2RX2DNPH1TAS1R3TAS1R1 | |
| SCHEMBL14946398 | 0.91 | P2RX3 (0.73) | P2RX3P2RX2DNPH1TAS1R3TAS1R1 | |
| SCHEMBL14929323 | 0.91 | P2RX3 (0.73) | P2RX3P2RX2DNPH1TAS1R3TAS1R1 | |
| SCHEMBL14946385 | 0.89 | SLC29A1 (0.64) | ADORA1ADORA3SLC29A1ADORA2A | |
| SCHEMBL14853952 | 0.89 | SLC29A1 (0.64) | ADORA1ADORA3SLC29A1ADORA2A | |
| SCHEMBL11267406 | 0.89 | P2RX3 (0.65) | P2RX3P2RX2DNPH1TAS1R3TAS1R1 | |
| SCHEMBL14853949 | 0.88 | P2RX3 (0.67) | P2RX3P2RX2DNPH1TAS1R3TAS1R1 | |
| SCHEMBL14948866 | 0.84 | P2RX3 (0.66) | P2RX3P2RX2DNPH1TAS1R3TAS1R1 | |
| SCHEMBL91052 | 0.83 | SLC29A1 (0.58) | P2RX3P2RX2ADORA1ADORA3SLC29A1 | |
| SCHEMBL15305350 | 0.83 | P2RX3 (0.67) | P2RX3P2RX2DNPH1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RX3 736/4885P2RX2 904/4885DNPH1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.